AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02756962 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClinSeq
Description: Clinical Sequencing to determine clearance or persistence of leukemia-associate mutations performed at MGI CLIA lab
Study NCT00873223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Subjects will self-inject liraglutide subcutaneously daily during the trial and three euglycemic clamps will be performed: one without liraglutide (insulin detemir alone), the second with only liraglutide treatment and the third with liraglutide and insulin detemir administration
Study NCT00873223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Subjects will self-inject liraglutide subcutaneously daily during the trial and three euglycemic clamps will be performed: one without liraglutide (insulin detemir alone), the second with only liraglutide treatment and the third with liraglutide and insulin detemir administration
Study NCT00948987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 325 mg enteric coated single dose p.o.
Study NCT03692065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban 5 MG
Description: Subjects will be randomized (1:1 ratio) to apixaban 5 mg bid (full dose) or apixaban 2.5 mg bid (reduced-dose) using a centralized IWRS (double blind study).
Study NCT02612324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pono Choices
Description: Medically accurate teen pregnancy and STI prevention education delivered through a place-based framework integrating Hawaiian cultural activities that draw upon both historical and local references.
Study NCT03423030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169 Formulation
Description: PBTZ169 Formulation supplied as powder for oral solution
Study NCT04436250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: The active comparator is composed of clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride
Study NCT04436250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active comparator
Description: The active comparator is composed of clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride
Study NCT04436250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-Ketamine Low dose
Description: The arm 1 is composed of esketamine 0.2 mg/kg and clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride.
Study NCT04436250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-Ketamine High dose
Description: The arm 2 is composed of esketamine 0.4 mg/kg and clonidine 1 microg/kg combined with magnesium sulfate 40 mg/kg diluted in 45 ml of sodium chloride.
Study NCT03206086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Daily dose - Non-Asian (>=12): 150 mg Non-Asian (6-11): 75 mg East Asian, South East Asian (>=12): 75 mg East Asian, South East Asian (6-11): 37.5 mg
Study NCT02397096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doravirine, Tenofovir, Lamivudine
Description: Single tablet containing MK-1439 (doravirine) 100 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300 mg
Study NCT02397096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine, Tenofovir, Lamivudine
Description: Single tablet containing MK-1439 (doravirine) 100 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300 mg
Study NCT02397096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor
Description: Baseline regimen of antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) administered according to the product circular
Study NCT02397096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor
Description: Baseline regimen of antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) administered according to the product circular
Study NCT02397096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baseline regimen of cobicistat-boosted elvitegravir
Description: Baseline regimen of antiretroviral therapy with cobicistat-boosted elvitegravir administered according to the product circular
Study NCT02397096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baseline regimen of cobicistat-boosted elvitegravir
Description: Baseline regimen of antiretroviral therapy with cobicistat-boosted elvitegravir administered according to the product circular
Study NCT03423030 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo supplied as powder for oral solution
Study NCT02397096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baseline regimen of a non-nucleoside reverse transcriptase inhibitor
Description: Baseline regimen of antiretroviral therapy with a NNRTI (efavirenz, nevirapine, or rilpivirine) administered according to the product circular
Study NCT02397096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baseline regimen of a non-nucleoside reverse transcriptase inhibitor
Description: Baseline regimen of antiretroviral therapy with a NNRTI (efavirenz, nevirapine, or rilpivirine) administered according to the product circular
Study NCT02397096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baseline regimen of two nucleoside reverse transcriptase inhibitors
Description: Baseline regimen of antiretroviral therapy with two NRTIs administered according to the product circular
Study NCT02397096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baseline regimen of two nucleoside reverse transcriptase inhibitors
Description: Baseline regimen of antiretroviral therapy with two NRTIs administered according to the product circular
Study NCT03542279 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE)
Description: PE is performed every other day using a multi-filtrate apheresis device (Fresenius, Bad Homburg, Germany), and 5 times in total for each course. The plasma removed during PE is replaced with an equal volume of substitution (half 5% albumin with normal saline and half plasma). The plasma volume to be replaced was estimated according to the following formula: plasma volume (L) = 7.5%×weight (kg)×(1-hematocrit)×1000ml. Heparin was added to the exchange circuit to prevent blood clotting. The exchange rate was monitored, recorded, and balanced to prevent cardiovascular instability. Blood pressure and other vital signs were closely monitored every 15 minutes throughout the exchange.
Study NCT03542279 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plasma exchange (PE)
Description: PE is performed every other day using a multi-filtrate apheresis device (Fresenius, Bad Homburg, Germany), and 5 times in total for each course. The plasma removed during PE is replaced with an equal volume of substitution (half 5% albumin with normal saline and half plasma). The plasma volume to be replaced was estimated according to the following formula: plasma volume (L) = 7.5%×weight (kg)×(1-hematocrit)×1000ml. Heparin was added to the exchange circuit to prevent blood clotting. The exchange rate was monitored, recorded, and balanced to prevent cardiovascular instability. Blood pressure and other vital signs were closely monitored every 15 minutes throughout the exchange.
Study NCT03542279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous immunmoglobulin (IVIG), intravenous methylprednisolone (IVMP)
Description: IVIG is given 0.4 g/kg/d for each course for 5 days. IVMP is 1,000 mg or 500 mg methylprednisolone for 3 or 5 days, and the dosage of glucocorticoid will gradually decrease.
Study NCT03542279 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous immunmoglobulin (IVIG), intravenous methylprednisolone (IVMP)
Description: IVIG is given 0.4 g/kg/d for each course for 5 days. IVMP is 1,000 mg or 500 mg methylprednisolone for 3 or 5 days, and the dosage of glucocorticoid will gradually decrease.
Study NCT03423030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: matching placebo supplied as powder for oral solution
Study NCT03423030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169 NCP
Description: PBTZ169 NCP supplied as powder for oral solution
Study NCT01688245 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS Assessments & Feedback
Description: Weekly pre-weekend drinking plan and post-weekend drinking outcome assessments with personlaized feedback
Study NCT01688245 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS Assessments
Description: Weekly post-weekend drinking outcome assessments
Study NCT03184493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celebrex plus Metformin
Description: This group patients will receive metformin and celebrex.
Study NCT03184493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celebrex
Description: This group patients will receive celebrex.
Study NCT03184493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: This group patients will receive metformin.
Study NCT00566982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg
Description: 60 mg/day (QD) dose of ospemifene (1 tablet) will be taken for 52 weeks - from Visit 2 (Randomization, Day 1) to Visit 6 (End of Therapy or Early Discontinuation, Week 52). Dosing will be oral and the ospemifene 60 mg tablet will be taken once daily, in the morning, with food.
Study NCT00566982 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosing will be oral and placebo will be taken once daily, in the morning, with food for 52 weeks - from Visit 2 (Randomization, Day 1) to Visit 6 (End of Therapy or Early Discontinuation, Week 52)
Study NCT00779428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tanespimycin
Description: Solution, IV~This is a one arm study with the dose, frequency, and duration assigned as per previous protocol (KOS-953, 17-AAG)
Study NCT03691337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine 0.25 % Injectable Solution
Description: Fascia iliaca block with volume 0.11 mL x subject height
Study NCT03691337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine 0.25 % Injectable Solution
Description: Fascia iliaca block with volume 0.22 mL x subject height
Study NCT03691337 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Fascia iliaca block with volume 0.11 mL x subject height
Study NCT02582814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Description: Dapagliflozin, a blood glucose lowering drug. Oral dose
Study NCT02582814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: Dapagliflozin, a blood glucose lowering drug. Oral dose
Study NCT00528502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine is misted into the air that you breathe during the surgery.
Study NCT00528502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline is misted into the air that you breathe during the surgery.
Study NCT03530995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil
Description: Development candidate
Study NCT03530995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Perpetrator drug
Study NCT03530995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Perpetrator drug
Study NCT03530995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Perpetrator drug
Study NCT03530995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Perpetrator drug
Study NCT02612324 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Business as Usual
Description: Teen pregnancy and STI prevention education left to the discretion of the school.
Study NCT03180723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous injection
Study NCT03180723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin
Description: Oral tablets
Study NCT03780855 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nerve scaffold
Description: It is a new kind of nerve scaffold with the microstructure of longitudinally oriented microchannels. It's made of collagen as the main raw material.
Study NCT01088945 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Discharge process
Description: Health Coaching prior to discharge, with an enhanced discharge binder to reinforce the teaching of the Health Coach
Study NCT01088945 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Discharge process
Description: Health Coaching prior to discharge, with an enhanced discharge binder to reinforce the teaching of the Health Coach
Study NCT02599129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: subcutaneous secukinumab (300 mg) at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including Week 20.
Study NCT02599129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ￼subcutaneous placebo at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including week 20.
Study NCT01228760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASG-5ME
Description: IV
Study NCT00218634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-AD
Description: Cognitive behavioral therapy for adherence and depression consisting of 1 session focusing on adherence and 8 sessions consisting of cognitive behavioral therapy for medication adherence and depression.
Study NCT00218634 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ETAU
Description: Enhanced treatment as usual consisting of 1 session focused on adherence (the same session as the CBT-AD intervention) and 8 sessions for participants to complete self-reports and collect adherence data.
Study NCT02482597 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Whole Body Periodic Acceleration
Description: A bed that translates back and forth at different frequencies while the subject lies supine
Study NCT02482597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole Body Periodic Acceleration
Description: A bed that translates back and forth at different frequencies while the subject lies supine
Study NCT05390281 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: increase in serum creatinine
Description: any of the following: increase in serum creatinine by ≥ 0.3 mg/dl within 48 h of surgery or increase in serum creatinin
Study NCT00678769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Given IV
Study NCT00678769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00678769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00678769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study NCT03786081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tisotumab Vedotin
Description: Given into the vein (IV)
Study NCT03786081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given via IV
Study NCT03786081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given via IV
Study NCT03786081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given via IV
Study NCT03489655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maintenance Phase Intervention
Description: The CHW will utilize motivational interviewing techniques over phone calls to reinforce all asthma education provided in the AI phase, including asthma basics, triggers and reduction strategies, purpose of medications, and steps for proper medication use. The CHW will identify barriers the participant is facing in management of their asthma and set goals to overcome them. The CHW will encourage regular visits with the Primary Care Physician and assist with referrals for other medical and social services, as needed. CHWs will check-in with participants via phone, monthly for the first 6 months and bi-monthly in the remaining 6 months Participants will receive bi-monthly data collection follow-up phone calls by a Research Assistant.
Study NCT02661555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Study NCT01932229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib treatment
Study NCT03037476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based PFI
Description: A web-based 5 component Personalized Feedback Tool covering content on: 1) Stimulants, 2) Marijuana, 3) PSM and unwanted effects, 4) Academics, and 5) Alcohol.
Study NCT03037476 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Assessment Only
Description: The Assessment Only condition receives assessment on substance use, health behaviors, and academic behaviors at baseline, 6 month follow-up, and 12 month follow-up.
Study NCT05611567 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: POSE2.0 procedure
Description: The POSE 2.0 involves full-thickness plications by suture anchor pairs that shorten and tabularize the stomach along its greater curvature. The POSE 2.0 procedure was carried out using the Incisionless Operating Platform (USGI Medical, San Clemente, CA)
Study NCT05611567 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life style and behavioral intervention
Description: The intervention focuses on caloric restriction diet, physical activity, and behavioral modification targeted toward weight loss and administered by a health care professional months for the 12 months duration of the study.
Study NCT05611567 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life style and behavioral intervention
Description: The intervention focuses on caloric restriction diet, physical activity, and behavioral modification targeted toward weight loss and administered by a health care professional months for the 12 months duration of the study.
Study NCT01033006 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Arm 1: catheter injection
Study NCT01033006 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Arm 2: transarterial injection
Study NCT01033006 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Arm 3: catheter and transarterial injection
Study NCT03418311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical Pessary-Group
Description: Placement of the cervical pessary (non-invasive) at enrolment including a transvaginal ultrasound to verify its correct fit. Removal of the cervical pessary (non-invasive) in a regular preventive examination at week of gestation 37+0. Except for placement/removal of cervical pessary the pregnant women will receive the usual care.
Study NCT00263042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimonabant
Description: Tablet, oral administration
Study NCT00263042 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Rimonabant)
Description: Tablet, oral administration
Study NCT01152918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Linkage-to-Care Component: Financial Incentive (FI)
Description: Test sites assigned to this arm will provide coupons to all people who are found to be HIV-infected after testing and who are not already linked to HIV care. The coupons can be redeemed at a participating HIV care site for gift cards.
Study NCT01152918 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Linkage-to-Care Component: Standard of Care (SOC)
Description: Each person who receives an HIV positive test result, and is not currently in care, will be directed to HIV care sites using the site's SOC procedures.
Study NCT01152918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Viral Suppression Component: FI
Description: HIV-infected participants who are receiving ART will be offered FIs upon the confirmation of each suppressed viral load measurement (less than 400 copies/mL).
Study NCT01152918 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Viral Suppression Component: SOC
Description: HIV-infected participants who are receiving ART will be offered support via the site's SOC procedures to attend HIV care site visits and remain adherent to their ART regimen in order to achieve and maintain viral load suppression.
Study NCT01152918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention for Positives Component: Counseling and SOC
Description: Participants will complete a computer-delivered counseling program that emphasizes HIV prevention strategies for HIV-infected people.
Study NCT01152918 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevention for Positives Component: SOC
Description: Participants will receive SOC from their HIV care site.
Study NCT04622891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500mg
Description: clarithromycin 500